Investors in Strata Critical Medical, Inc. (NASDAQ:SRTA) had a good week, as its shares rose 9.8% to close at US$5.59 following the release of its second-quarter results. Revenues of US$73m beat expectations by a respectable 7.2%, although statutory losses per share increased. Strata Critical Medical lost US$0.12, which was 500% more than what the analysts had included in their models. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

After the latest results, the four analysts covering Strata Critical Medical are now predicting revenues of US$285.6m in 2026. If met, this would reflect a notable 12% improvement in revenue compared to the last 12 months. Earnings are expected to improve, with Strata Critical Medical forecast to report a statutory profit of US$0.0033 per share. Before this latest report, the consensus had been expecting revenues of US$274.4m and US$0.04 per share in losses. The analysts have definitely been lifting their expectations, with the company expected to reach profitability next year - sooner than expected - thanks to the small lift in revenue expectations.

Despite these upgrades,the analysts have not made any major changes to their price target of US$9.56, suggesting that the higher estimates are not likely to have a long term impact on what the stock is worth. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Strata Critical Medical analyst has a price target of US$12.75 per share, while the most pessimistic values it at US$8.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Strata Critical Medical's growth to accelerate, with the forecast 24% annualised growth to the end of 2026 ranking favourably alongside historical growth of 19% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 5.0% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Strata Critical Medical to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts now expect Strata Critical Medical to become profitable next year, compared to previous expectations that it would report a loss. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Strata Critical Medical. Long-term earnings power is much more important than next year's profits. We have forecasts for Strata Critical Medical going out to 2027, and you can see them free on our platform here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.